To realize the huge translational potential of Dr. Meyer’s innovative research, and to deliver it to women everywhere, CAMH has signed a deal with a global pharmaceutical company to assist in the development and commercialization of the dietary supplement. The product could be available to women around the world within the next few years.
Developing successful nutrition-based treatments, based on neurobiology, is rare in psychiatry. We believe our approach also represents a promising new avenue for creating other new dietary supplements for medicinal use.
Dr. Meyer continues to look for biomarker signatures and patterns that may help unravel the mysteries of the brain, both the specific kind of proteins used in the postpartum depression study as well as the functioning of the whole brain as found in the inflammation study.
"I am very optimistic that over the next 20 years we are going to identify more specific aspects of the neurobiology of mental illness, and in particular Major Depressive Disorder, and be able to link those into the therapeutic streams and develop more individualized treatment."